Avastin® (bevacizumab) Dosing | MCRC Treatment
Colorectal Cancer – Treatments | Gastrointestinal Cancer
Bevacizumab (Avastin®) as maintenance therapy after first progression on bevacizumab for patients with advanced colorectal carcinoma | Semantic Scholar
Capecitabine (Xeloda) for Colon Cancer | ChemoExperts
Use of Bevacizumab in the Maintenance Setting for Patients with Metastatic Colorectal Cancer (mCRC) | Research To Practice
Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
1175-Colorectal metastatic capecitabine and beVACizumab | eviQ
Benefits & Risks of Treatment | Metastatic Colorectal Cancer (mCRC)| Avastin® (bevacizumab)
Erbitux®/Avastin®/Camptosar® Appears Effective in Colorectal Cancer Patients - CancerConnect
Evidence Based Management of Newly Diagnosed Metastatic Colorectal Cancer | CME
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label,
Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer | BMC Cancer
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised ...
Trifluridine/Tipiracil Combination Misses Mark in Metastatic Colon Cancer | MedPage Today
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
Maintenance Treatment With Capecitabine and Bevacizumab Is Effective in Metastatic Colorectal Cancer - The ASCO Post
Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
New Treatment Options for Colorectal Cancer
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram
New Colon Chemotherapy
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer | NEJM
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer | British Journal of Cancer
